Author/Creator: Kong, Danqing - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Kong, Danqing

1. Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Issue 2 (28th January 2022)

Authors:: Kong, Danqing; Li, Yun; Fu, Chengcheng; Hou, Mengjia; Yan, Lingzhi; Shang, Jingjing; Wang, Zhaoyue; Yin, Jie; Yu, Ziqiang; Wu, Depei
Journal:: Leukemia & lymphoma
Issue:: Volume 63:Issue 2(2022)
Page Start:: 491
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment. (8th September 2022)

Authors:: Yin, Jie; Tian, Hong; Kong, Danqing; Li, Yun; Gu, Chengyuan; Wang, Zhaoyue; Wu, Depei; Yu, Ziqiang
Journal:: British journal of haematology
Issue:: Volume 199:Number 4(2022)
Page Start:: 619
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. CAR‐T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph+ mixed phenotype acute leukaemia with minimal residual disease. (22nd July 2020)

Authors:: Kong, Danqing; Qu, Changju; Dai, Haiping; Li, Zheng; Yin, Jia; Chen, Suning; Kang, Liqing; Chen, Guanghua; Zhu, Mingqing; Yu, Lei; Wu, Depei; Tang, Xiaowen
Journal:: British journal of haematology
Issue:: Volume 191:Number 2(2020)
Page Start:: e47
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Dual epigenetic agents plus rituximab–gemcitabine–oxaliplatin as salvage treatment in relapsed/refractory diffuse large B‐cell lymphoma patients failure of salvage chemotherapy. Issue 5 (12th August 2022)

Authors:: Qu, Changju; Ping, Nana; Kong, Danqing; Liu, Aining; Liu, Hailing; Xu, Ting; Xia, Fan; Wu, Depei; Jin, Zhengming
Journal:: Hematological oncology
Issue:: Volume 40:Issue 5(2022)
Page Start:: 914
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. Issue 1 (January 2020)

Authors:: Qu, Changju; Ping, Nana; Kang, Liqing; Liu, Hailing; Qin, Songbin; Wu, Qian; Chen, Xiaochen; Zhou, Meng; Xia, Fan; Ye, Aihua; Kong, Danqing; Li, Caixia; Yu, Lei; Wu, Depei; Jin, Zhengming
Journal:: Journal of immunotherapy
Issue:: Volume 43:Issue 1(2020:Jan.)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant. (18th August 2022)

Authors:: Tian, Hong; Kong, Danqing; Li, Yun; Gu, Chengyuan; Yu, Ziqiang; Wang, Zhaoyue; Wu, Depei; Yin, Jie
Journal:: Platelets
Issue:: Volume 33:Number 6(2022)
Page Start:: 951
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. The coexistence of antiβ2 glycoprotein 1 antibody antibody has no effect on hemophilia A patient. Issue 6 (September 2022)

Authors:: Yu, Xiuqun; Kong, Danqing; Wang, Zhaoyue; Yin, Jie; Yu, Ziqiang
Journal:: Blood coagulation and fibrinolysis
Issue:: Volume 33:Issue 6(2022)
Page Start:: 348
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗